Does Blue Cross Blue Shield of Alabama Cover Forteo?

What Is Forteo and Why Does Coverage Matter?

Forteo (teriparatide) is a recombinant parathyroid hormone analog that stimulates new bone formation rather than simply slowing bone loss. The FDA approved teriparatide on November 26, 2002, for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis. [1]

Coverage decisions matter enormously here because the drug's retail price sits near $3,000 per 28-day pen, placing it among the most expensive outpatient bone-health therapies available. Without active insurance approval, most patients simply cannot afford the 18-to-24-month treatment course that trials show is necessary to produce clinically meaningful bone mineral density gains.

How Teriparatide Works

Teriparatide binds to the PTH/PTHrP receptor on osteoblasts, increasing osteoblast activity faster than osteoclast activity during the first several months of treatment. The net effect is an anabolic gain in trabecular and cortical bone. In the key Fracture Prevention Trial (N=1,637 postmenopausal women), teriparatide 20 mcg/day reduced new vertebral fractures by 65% (RR 0.35, 95% CI 0.22-0.55, P<0.001) and non-vertebral fragility fractures by 53% compared with placebo over a median 19 months. [2]

Why the 24-Month Cap Exists

The FDA placed a 24-month lifetime limit on teriparatide use based on rat carcinogenicity data showing dose-dependent osteosarcoma at supratherapeutic exposures. [1] Most payers, including BCBSAL, mirror this cap in their coverage criteria. Because this limit is embedded in the FDA label itself, appeals to extend beyond 24 months are rarely successful.

Does BCBSAL Specifically Cover Forteo?

BCBSAL does list teriparatide on its formulary for most commercial, marketplace, and Medicare Advantage plans, but it sits on a specialty tier that triggers both prior authorization and, on many plans, step-therapy requirements. The specific formulary tier and cost-sharing depend on the employer group or individual plan selected.

Commercial and Marketplace Plans

On BCBSAL commercial plans, Forteo typically falls on Tier 4 or Tier 5 (specialty). Copay or coinsurance for specialty drugs commonly ranges from 25-33% of the negotiated rate after deductible, which can still represent hundreds of dollars per fill even with insurance active.

Step therapy on commercial plans generally requires documented inadequate response or intolerance to at least one oral bisphosphonate (alendronate, risedronate, or ibandronate) before Forteo is approved as a first-line anabolic agent. The American Association of Clinical Endocrinologists 2020 guidelines do support first-line anabolic therapy for patients with very high fracture risk (T-score <-3.0, multiple vertebral fractures, or prior hip fracture), [3] and that documentation can satisfy the step-therapy exception pathway.

Medicare Advantage Plans

BCBSAL administers several Medicare Advantage plans in Alabama. Teriparatide under Medicare is typically covered under Part D (pharmacy benefit) rather than Part B, because patients self-administer the injection at home. Part D formularies are plan-specific and change annually. Patients should check the current plan's Evidence of Coverage document or call the Member Services number on the back of their insurance card each January.

Medicaid Managed Care

For patients enrolled in a BCBSAL-administered Alabama Medicaid managed care plan, teriparatide coverage is subject to Alabama Medicaid Agency drug policy. Alabama Medicaid has historically required prior authorization with evidence of severe osteoporosis (T-score <-3.0 or at least one fragility fracture) and bisphosphonate failure or intolerance before approving anabolic therapy.

Prior Authorization Criteria: What BCBSAL Typically Requires

Prior authorization (PA) is the single biggest barrier patients face. Understanding the specific clinical criteria that BCBSAL reviewers assess allows prescribers to front-load the right documentation and avoid the most common denial reasons.

Standard Clinical Requirements

Most BCBSAL prior authorization criteria for teriparatide include the following elements. The prescriber must document:

• A confirmed diagnosis of osteoporosis by DXA scan, with T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip.
• Or a T-score between -1.0 and -2.5 (osteopenia range) combined with at least one low-trauma or fragility fracture.
• Failure, contraindication, or documented intolerance to at least one first-line oral bisphosphonate, unless the patient meets very-high-risk criteria per published guidelines. [3]
• The prescriber must be an appropriate specialist (endocrinologist, rheumatologist, or orthopedic surgeon with osteoporosis expertise) on many plans, though primary care prescriptions are accepted on others.

Documentation the Prescriber Should Submit

Incomplete submission is the leading cause of initial PA denial. The prescriber's office should include:

1. The most recent DXA report with numeric T-scores and Z-scores at all measured sites.
2. Relevant imaging reports (spine X-ray or CT scan) documenting any vertebral fractures.
3. Medication history confirming prior bisphosphonate use, dose, duration, and reason for discontinuation (if applicable).
4. Lab results ruling out secondary causes of bone loss: serum calcium, 25-OH vitamin D, PTH, TSH, and complete metabolic panel. [4]
5. A clinical narrative from the prescriber explaining why teriparatide is appropriate for this specific patient.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "In postmenopausal women with osteoporosis at high risk of fracture, we suggest treatment with anabolic agents (teriparatide, abaloparatide, or romosozumab) as initial therapy." [5] Quoting guideline language directly in the PA letter can improve approval rates.

Turnaround Times

Standard PA reviews at most BCBSAL plans take 3-5 business days. Urgent or expedited requests (where delay would seriously jeopardize the patient's health) must be completed within 72 hours under federal managed care regulations. [6]

What to Do If BCBSAL Denies Coverage

Denial does not end the process. Patients and prescribers have several formal and informal options.

Internal Appeal

Federal law (the Affordable Care Act and ERISA for employer-sponsored plans) guarantees the right to at least one internal appeal. [7] The appeal must be filed within 180 days of receiving the denial notice for ACA-regulated plans. A strong appeal includes:

• A letter of medical necessity written by the treating physician, citing specific guideline language and the patient's fracture risk score (FRAX score).
• Peer-reviewed literature supporting teriparatide for the patient's specific clinical scenario.
• Any prior bisphosphonate adverse-event records (esophageal irritation, atypical femoral fracture concern, jaw osteonecrosis history, severe renal impairment with CrCl <35 mL/min making bisphosphonates contraindicated). [8]

External Independent Review

If the internal appeal fails, patients covered by ACA-regulated plans have the right to an independent external review by an accredited Independent Review Organization (IRO). BCBSAL must provide IRO contact information in the denial letter. The IRO's decision is binding on BCBSAL. For self-insured employer plans governed by ERISA, external review procedures vary by plan document.

Peer-to-Peer Review

Many BCBSAL PA decisions can be reconsidered through a peer-to-peer call between the prescribing physician and a BCBSAL medical director. This call typically must be requested within 5-10 business days of the denial. In practice, peer-to-peer calls resolve a meaningful fraction of specialty drug denials before the formal appeal stage.

FRAX Score and Why It Matters for Coverage

The FRAX tool, developed by the World Health Organization, calculates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors with or without DXA T-score. [9] BCBSAL reviewers and treating physicians both use FRAX thresholds endorsed by the National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation, BHOF):

• Major osteoporotic fracture probability at or above 20%, or
• Hip fracture probability at or above 3%.

Either threshold, per BHOF guidance, justifies pharmacologic treatment initiation. [10] For teriparatide specifically, the relevant threshold is a "very high fracture risk" classification, defined by the AACE/ACE 2020 guidelines as FRAX 10-year major fracture probability above 30% or hip fracture above 4.5%, T-score at or below -3.0, or a history of hip or spine fracture. [3]

Prescribers who include the patient's printed FRAX calculation in the PA submission give the reviewer a standardized, internationally recognized quantitative risk estimate, which is harder to dismiss than qualitative language alone.

Calculating FRAX for Your Patient

The online FRAX calculator is freely available at the University of Sheffield website and accepts inputs for age, sex, body mass index, prior fracture, parental hip fracture, smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, and alcohol consumption. With a DXA T-score entered, the calculation becomes more precise. The output is a percentage, not a category, so even patients in the osteopenia T-score range can qualify for treatment if their absolute fracture probability crosses guideline thresholds. [9]

Cost-Reduction Strategies When Coverage Is Partial or Denied

Even with an active BCBSAL prior authorization, specialty-tier cost-sharing can be substantial. Several programs exist to reduce out-of-pocket burden.

Lilly Cares Foundation

Eli Lilly operates the Lilly Cares Foundation patient assistance program, which may provide Forteo at no cost to uninsured or underinsured patients meeting income criteria. Commercially insured patients may access Lilly's co-pay assistance card, which has historically reduced co-pays to as low as $0 per month for eligible patients. [11] Co-pay cards are generally not usable for federally funded insurance (Medicare, Medicaid), due to federal anti-kickback statute restrictions.

Biosimilar and Generic Teriparatide

Two FDA-approved teriparatide products compete with brand-name Forteo:

• Bonsity (teriparatide, Radius Health / Teva): FDA-approved March 2021. [12]
• Tlando: Note, Tlando is a testosterone product; the relevant competitor is Tymlos (abaloparatide), a related but distinct PTH analog, not a teriparatide generic.

Generic teriparatide (Bonsity) carries a meaningfully lower list price than Forteo. BCBSAL formularies may prefer the generic and require a PA exception or brand-name justification to dispense brand Forteo instead. Prescribers should confirm which teriparatide product appears on the patient's specific plan formulary before writing the prescription.

Abaloparatide as an Alternative Anabolic Agent

Abaloparatide (Tymlos, Radius Health) received FDA approval in April 2017 for postmenopausal osteoporosis. [13] In the ACTIVE trial (N=2,463), abaloparatide 80 mcg/day reduced new vertebral fractures by 86% (RR 0.14, 95% CI 0.05-0.39, P<0.001) vs. Placebo over 18 months. [14] Some BCBSAL formularies tier abaloparatide differently than teriparatide, and it may face fewer step-therapy requirements on certain plans. If teriparatide PA is denied, asking the prescriber to submit a PA for abaloparatide is a reasonable clinical and administrative alternative.

Romosozumab as a High-Risk Option

Romosozumab (Evenity, Amgen/UCB) is an anti-sclerostin monoclonal antibody with a dual anabolic-antiresorptive mechanism approved by the FDA in April 2019. [15] In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced vertebral fracture risk by 48% vs. Alendronate alone. [16] Romosozumab carries a boxed warning for cardiovascular risk and is contraindicated within 12 months of MI or stroke, which the prescriber must address in any PA submission. Coverage criteria under BCBSAL differ from teriparatide criteria, so reviewing the specific romosozumab PA policy is worthwhile before switching.

Sequential Therapy: What Happens After Forteo

The 24-month FDA lifetime cap on teriparatide means every patient needs a transition plan. Stopping teriparatide without starting an antiresorptive leads to rapid bone loss within 12 months of discontinuation. [17] Endocrine Society guidelines recommend sequential antiresorptive therapy (typically a bisphosphonate, with denosumab as an alternative) immediately after completing teriparatide. [5]

Bisphosphonate Sequencing

Alendronate 70 mg weekly or zoledronic acid 5 mg IV annually are the most studied post-teriparatide antiresorptives. The DATA-Switch trial (N=94) showed that patients who transitioned from teriparatide to denosumab gained an additional 6.8% lumbar spine BMD over 24 months, outperforming the teriparatide-to-alendronate transition. [18] Prescribers should document the planned sequential therapy in the original PA submission; some BCBSAL reviewers view a complete treatment plan favorably.

Coverage for Sequential Agents

Alendronate is available as a low-cost generic (often $4-10/month at retail pharmacies) and does not require prior authorization on virtually any BCBSAL plan. Denosumab (Prolia) does require PA on most BCBSAL plans, with criteria centered on bisphosphonate intolerance or renal impairment. [19] Zoledronic acid is usually billed under the medical benefit as a physician-administered infusion and follows a separate PA pathway.

Monitoring Requirements During Teriparatide Treatment

BCBSAL may require evidence of appropriate monitoring as a condition of continued coverage beyond the initial approval period.

Laboratory and DXA Monitoring

The Endocrine Society recommends checking serum calcium 1-2 months after initiating teriparatide to screen for hypercalcemia, a known adverse effect. [5] DXA monitoring at 1-2 years during treatment documents the therapeutic response. Bone turnover markers (serum P1NP, a marker of bone formation) typically rise within 1-3 months of starting teriparatide and can serve as an early indicator of biological response. [20]

Standard monitoring values:

• Serum calcium: target 8.5-10.5 mg/dL.
• 25-OH vitamin D: maintain above 30 ng/mL (75 nmol/L) per Endocrine Society guidance. [5]
• Serum creatinine and estimated GFR: teriparatide is not recommended when CrCl <35 mL/min per prescribing information. [1]

Calcium and Vitamin D Supplementation

All patients on teriparatide should receive adequate calcium and vitamin D. The National Institutes of Health recommends 1,000-1,200 mg/day total calcium (diet plus supplement) for adults over 50, and the Endocrine Society recommends 1,500-2,000 IU/day of vitamin D3 for patients with osteoporosis requiring supplementation. [5] Documenting supplement use in the medical record supports the completeness of osteoporosis management and can strengthen PA submissions.

Calling BCBSAL: Practical Tips for Patients and Prescribers

Navigating insurance by phone goes more smoothly with preparation. Before calling the Member Services number on the back of the insurance card, have the following ready:

• Patient's member ID and group number.
• Forteo NDC number (ask the dispensing pharmacy) or the J-code if billed under medical benefit (J3490 or J3590 for unclassified biologics; teriparatide does not yet have a dedicated J-code as of early 2025).
• The prescribing physician's NPI number.
• The diagnosis code: ICD-10 M81.0 (age-related osteoporosis without pathological fracture) or M80.08XA/M80.88XA for fracture-related codes.

Ask the representative to confirm whether PA is required, the PA fax number for the prescriber's office, the formulary tier and co-pay amount, and whether a co-pay accumulator program applies to specialty co-pay cards (co-pay accumulators prevent manufacturer co-pay card payments from counting toward the patient's deductible, increasing net out-of-pocket cost significantly on some BCBSAL commercial plans).

State and Federal Protections Alabama Patients Should Know

Alabama follows federal ACA requirements for PA transparency and appeal rights on fully-insured plans. The Alabama Department of Insurance (ALDOI) regulates BCBSAL's commercial insurance products. Patients who believe a PA denial is improper can file a complaint with ALDOI online or by phone.

For step therapy specifically, Alabama enacted step therapy reform legislation (SB 207, effective 2019) requiring insurers to provide a clinical exception process for step therapy protocols when a patient has already tried and failed the required step drug, or when the required drug is clinically contraindicated. [21] This law gives prescribers a formal pathway to bypass bisphosphonate step therapy when the clinical record supports it.

Under the No Surprises Act (effective January 1, 2022), patients also have new rights related to cost transparency, though this law primarily addresses surprise billing for out-of-network care rather than drug formulary decisions. [22]